We invest in companies with compelling technology and promising initial human data.

Nexus NeuroTech Ventures, LLC is a venture capital firm based in San Francisco committed to advancing breakthrough technologies for brain disorders. We make seed and series A-C investments, and have the unique capacity to support earlier-stage programs not yet ready for formal venture capital investment through our Nexus NeuroTech Incubator Program.

Founded in 2023 by Jordi Parramon, PhD and William Marks, MD the firm brings a deep commitment to helping those with neurological and psychiatric disorders, such as Parkinson’s disease, bipolar disorder, and autism. Adjacent to these sentinel disorders are many other brain disorders that are also within scope for Nexus NeuroTech Ventures.

With the progress in understanding disease mechanisms and with advances in medical technology, we see an opportunity at this moment in time to pursue a portfolio of technology innovations aimed at addressing the spectrum of needs that patients face across their journey.

Nexus is differentiated by the partners’ operational oversight and deep domain expertise.

Nexus NeuroTech Ventures is building a portfolio that enables “connecting the dots” from a disease diagnosis and management perspective, providing a more holistic approach to brain disorders, with approaches spanning less invasive to more invasive therapeutic interventions, software- and hardware-based diagnostic technology, data platforms supporting clinical trials and clinical care, and tools directed at advancing therapy development and optimizing clinical care.  This provides a great opportunity to unlock efficiencies from a clinical and health economics perspective and from a technology perspective.

Nexus NeuroTech Ventures targets investments in companies with compelling technology and promising initial human data to enable their successful technological and business development, as well as clinical evidence generation and market access.